Symbols

INAB

In8bio·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Strong Buy"

MACD Death Cross

Ample Liquidity

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About INAB

In8bio, Inc.

A clinical-stage biopharmaceutical company that focused on gamma-delta T cell product candidates for solid and liquid tumors

Industry

Pharmaceutical

Established Date

02/08/2016

Listing Date

07/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.in8bio.com

Security Type

Common stock

Office address

350 5th Avenue, Suite 5330 , New York, New York 10118

Business

Introduction

In8 bio, Inc., was incorporated in Bermuda on February 8, 2016. The Company is a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapy candidates and gamma-delta T cell ligators for cancer and autoimmune diseases.

Company Financials

EPS

INAB has released its 2025 Q4 earnings. EPS was reported at -0.45, versus the expected -0.64, beating expectations. The chart below visualizes how INAB has performed over recent quarters, highlighting trends in earnings surprises.